Praecis Pharmaceuticals Inc.

Receive alerts:
by e-mail
E-mail Your information will be added to a database with the sole purpose of serving your subscription. This database is the exclusive property of vLex Networks S.L. and will never be shared with any other company. By sending your request you accept the Data Protection Policy of vLex Networks S.L. I have read and accept the Terms of Use
via RSS

122 documents for Praecis Pharmaceuticals Inc.

- Lerach Coughlin Stoia Geller Rudman & Robbins LLP Files Class Action Suit against Praecis Pharmaceuticals, Inc.
NEW YORK -- Lerach Coughlin Stoia Geller Rudman & Robbins LLP ("Lerach Coughlin") (http://www.lerachlaw.com/cases/praecis/) today announced that a cla...
- Business Wire
- January 21, 2005
- Human drugs: Patent extension; regulatory review period determinations PLENAXIS,
... period for a human drug product will include all of the testing phase and approval phase as spe...Patent No. 5,843,901) from Praecis Pharmaceuticals, Inc., and the Patent and Trademar...
- FR, September 29, 2006
- Notices
- Food and Drug Administration
- Praecis Pharmaceuticals Inc. CEO Interviewed by StreetSideInvestor.com.
Business Editors BLOOMINGTON, Ind.--(BUSINESS WIRE)--Jan. 11, 2001 Dr. Malcolm Gefter, Chairman, Chief Executive Officer, and President of Praecis...
- Business Wire
- January 11, 2001

- PRAECIS PHARMACEUTICALS INCORPORATED Announces Technology Transfer and Option Agreement with Gilead Sciences, Inc. to Utilize DirectSelect(TM) Technology.
WALTHAM, Mass. -- PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ: PRCS) today announced that it has signed a technology transfer and option agreement wi...
- Business Wire
- March 21, 2006
- Massachusetts is One of the Top Three States for Fast Growth Technology Companies; Thirty-One Massachusetts Companies Included in Deloitte & Touche 2001 Technology Fast 500.
...85 Praecis Medical/ Waltham MA 6,885% Pharmaceuticals, Inc. S...
- Business Wire
- November 14, 2001
- PRAECIS REPORTS DECREASED NET LOSS FOR QUARTER.
Praecis Pharmceuticals, Inc. (NASDAQ: PRCS), Waltham, Mass., has announced con.... Praecis Pharmaceuticals, Inc. is a biotechnology company focused on the di...
- Biotech Financial Reports
- Vol. 9 Nbr. 12, December 2002
- NormOxys, Inc. Appoints Dr. Gerard Riedel as Vice President, Regulatory Affairs and Program Management.
... joins NormOxys from Momenta Pharmaceuticals, Inc., where he served as Vice President, Regulato... Assurance and Project Management at PRAECIS Pharmaceuticals, Inc. Before joining PRAECIS, he h...
- Business Wire
- October 05, 2010
- Acceleron Appoints Kevin F. McLaughlin as Senior Vice President and Chief Financial Officer.
CAMBRIDGE, Mass. -- Acceleron Pharma, Inc., a biopharmaceutical company developing novel pro... held several executive positions with PRAECIS Pharmaceuticals, Inc. He joined the company as the...
- Business Wire
- November 29, 2010
- SRU Biosystems Appoints Richard Wagner, Ph.D., President and Chief Executive Officer.
... important benefits in one platform, including high throughput screening, streamlined and improve... Executive Vice President of Research at Praecis Pharmaceuticals, Inc., where he was an inventor of...
- Business Wire
- November 05, 2007
- JPMorgan Chase Reports First Quarter 2001 Results.
...Operating income was $1,436 million, compared with $763 million in ...CRWN 2.7 53 40 Praecis Pharmaceuticals Inc. PRCS 2.5 50 17 Wesco Internat...
- Business Wire
- April 18, 2001